Current Report Filing (8-k)
October 30 2020 - 3:16PM
Edgar (US Regulatory)
0001695357
false
0001695357
2020-10-28
2020-10-29
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): October 29, 2020
PROVENTION
BIO, INC.
Commission
File Number: 001-38552
Delaware
(State
or other jurisdiction
of
incorporation)
|
|
81-5245912
(IRS
Employer
Identification
No.)
|
|
|
|
P.O.
Box 666
Oldwick,
New Jersey
(Address
of principal executive offices)
|
|
08858
(Zip
Code)
|
(908)
336-0360
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol
|
|
Name
of each exchange on which registered
|
Common
Stock, $0.0001 par value per share
|
|
PRVB
|
|
The
Nasdaq Global Select Market
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
5.02
|
Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
|
Adoption
of Inducement Plan
On
October 29, 2020, the board of directors of Provention Bio, Inc. (the “Company”) approved the Provention Bio, Inc.
2020 Inducement Plan (the “2020 Inducement Plan”). Pursuant to the terms of the 2020 Inducement Plan, the Company
may grant nonstatutory stock options, stock appreciation rights, restricted stock unit awards and restricted stock for up to a
total of 2,000,000 shares of common stock to individuals that were not previously an employee or director of the Company or individuals
returning to employment after a bona fide period of non-employment with the Company. In accordance with Nasdaq Listing Rule 5635(c)(4),
the Company did not seek approval of the 2020 Inducement Plan by its stockholders.
The
foregoing is a brief description of the material terms of the 2020 Inducement Plan and is qualified in its entirety by reference
to the full text of the 2020 Inducement Plan filed as Exhibit 10.1 to this Current Report on Form 8-K.
Item
9.01
|
Financial
Statements and Exhibits.
|
(d)
The following exhibit is furnished with this report:
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date:
October 30, 2020
|
Provention Bio, Inc.
|
|
|
|
|
By:
|
/s/
Andrew Drechsler
|
|
|
Andrew
Drechsler
|
|
|
Chief
Financial Officer
|
Provention Bio (NASDAQ:PRVB)
Historical Stock Chart
From Jun 2024 to Jul 2024
Provention Bio (NASDAQ:PRVB)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Provention Bio Inc (NASDAQ): 0 recent articles
More Provention Bio, Inc. News Articles